Dehydropeptidase-1 (DPEP1) is a zinc-dependent metalloproteinase abnormally expressed in many cancers. However, its potential role in adults with B-cell acute lymphoblastic leukaemia (ALL) is unknown.
Introduction
Relapse is the leading cause of therapy-failure in adults with B-cell ALL. Many pre-therapy variables correlate with relapse risk but these are inaccurate in many instances and explain only about one-half of the variance in relapse outcomes. Consequently, new variables independently-correlated with relapse risk are needed. Dehydropeptidase-1 (DPEP1) is a zinc-dependent metalloproteinase. DPEP1 deletions are common in several cancers 1 . DPEP1 activity regulates concentrations of glutathione, leukotrienes and pro-inflammatory molecules associated with cancer development 2 . Several studies assessed DPEP1 transcript levels in diverse cancers. In some, transcript levels were prognostic and/or predictive of outcomes [3] [4] [5] . However, the role and clinical relevance of DPEP1 expression in cancer is controversial and molecular mechanism by which it acts may vary between cancers 4, 6-8 .
Persons with B-cell ALL have high DPEP1 transcript levels compared with normals 9 . However, the functional implication and clinical relevance of this observation, if any, is unknown. We evaluated DPEP1 transcript levels in bone marrow samples from adults with newly-diagnosed B-cell ALL. We found high DPEP1 transcript levels were associated with worse clinical outcomes. We also studied DPEP1 expression in a human B-cell ALL cell line and in a mouse xeno-transplant model. Our data suggest DPEP1 transcript levels independently-correlate with a higher cumulative incidence of relapse CIR and worse relapse-free survival (RFS) in adults with common B-cell ALL.
Materials and Methods

Subjects
Bone marrow samples were obtained from 235 consecutive adults (>16 years) with new-diagnosed, untreated B-cell ALL and 28 normals at the Hematology Department of Peking University Peoples Hospital March, 2009 to March, 2016. Subjects were followed until death, loss to follow-up or June, 2018.
Risk-stratification and therapy details are published 10, 11 .
Subjects with BCRABL1 (N=91) also received tyrosine kinase-inhibitors 11 .
Subjects achieving complete remission (N=208; 85%) were included in analyses of predictive variables. Because prognosis depends on ALL subtype, we pre-specified a separate analysis of CIR and RFS in subjects with common B-cell ALL (N=167). There were too few subjects with pre-B-cell ALL (N=14) and pro-B-cell ALL (N=27) to separately analyze for CIR and RFS.
105 subjects with common-B-cell ALL received an allotransplant 21 from an HLA-identical sibling and 84, from a HLA-haplotype-matched relative. 12, 13 .
The study was approved by the Ethics Committee of Peking University Peoples Hospital. Written informed consent was obtained according to the Declaration of Helsinki.
Leukemia cell lines
Human leukemia cell lines, including SUP-B15, BALL-1, Nalm6, KG-1, NB4, 11 . MRD was quantified by analyzing leukemia-associated aberrant immune phenotypes (LAIPs) by4-color flow cytometry as described 15 . A positive MRD-test was defined as ≥0.1% of cells with an LAIP phenotype in ≥1 bone marrow sample in 1 st complete remission 15 . Cytogenetic analyses were performed by G-banding 16 . BCRABL1 transcripts and KMT2A (MLL) rearrangements were detected with quantitative real-time polymerase chain reaction (RT-qPCR) 17, 18 . IKZF1 deletion was detected as described 10 . Risk cohort was defined as previously described 11 .
Lentiviral transduction
BV173 or BALL-1 cells were infected with human DPEP1 over-expression lentivirus or DPEP1 shRNA lentivirus or corresponding blank control (GeneChem, Shanghai, China, MOI=100). Media containing lentiviral particles were replaced with complete medium 12 h post-infection and stably-transfected BV173 cells were selected with 0.5 μg/ml puromycin dihydrochloride (GeneChem) for ≥6 w post-infection. DPEP1 expression levels were confirmed by RT-qPCR and western blotting.
RNA preparation and RT-qPCR
Mononuclear cells were isolated from bone marrow samples by
Ficoll-Hypaque TM density gradient centrifugation. RNA extraction and cDNA synthesis were performed as described. mRNA expression levels were determined by TaqMan 19® . DPEP1 transcript levels were normalized to ABL1 expression as recommended 20 . Copy numbers of DPEP1 and ABL1 were calculated from standard curves using Ct values. Samples were assayed in triplicate and average threshold Ct values calculated.
Western blotting
Cells were lysed in the presence of protease cocktail inhibitor, soluble lysates electrophoresis on SDS-polyacrylamide gels and transferred to a polyvinylidene fluoride membrane (Bio-Rad, Hercules, CA, US). Membranes were probed with specific antibodies and signals visualized using Odyssey Infrared Imaging System (LI-COR Biosciences, Lincoln, NE, US). GAPDH was used as a loading control.
Cell proliferation and viability assay
Proliferation was determined with the Cell Counting Kit-8 assay (CCK8, Dojin Laboratories, Kumamoto, Japan). Briefly, cells were seeded into 96-well plates at a density of 4×10E4 according to the manufacturer's instructions. Plates were scanned by a microplate reader at 450 nm at indicated time points. CCK8 was also used to determine cell viability after exposure to drugs, including daunorubicin, dexamethasone, methotrexate, cytarabine and imatinib (Solarbio, Beijing, China). Experiments were performed in triplicate.
Cell-cycle analyses
The cells were seeded onto 6-well plates and starved by adding serum-free medium for G 1 synchronization. After 24 h medium containing 10% fetal bovine serum was added for 48 h. Cells were fixed in 75% ethanol, stained with propidium iodide (BD Pharmingen, San Jose, CA, US) and analyzed by flow cytometry. Results were analyzed with ModFit LT2.0 software (Coulter Electronics, Hialeah, FL, USA).
Detection of apoptosis
Apoptosis was determined using the Annexin V-PI or Annexin V-7AAD Apoptosis Detection Kit (Sigma-Aldrich) according to the manufacturer's instructions. Samples were immediately analyzed by flow cytometry (Beckman Coulter). Approximately 5×10E+5 cells were analyzed in each sample.
Colony-forming assays
Cells were suspended in 1 mL of complete MethoCult TM medium and plated in 6 well plates at a concentration of 4 × 10E+3 cells/well. Colonies were maintained at 37°C with 5% CO 2 and 95% humidity for 7d, counted and scored after staining with 1% crystal violet (Sigma). Colonies of ≥50 cells were scored.
Assays were performed in triplicate. Experiments were done in triplicate. 
Cell migration and invasion assay
Tumor xenograft mouse model
Statistical analyses
Complete remission, relapse and refractory disease were defined as described 11 . Cumulative incidence of relapse (CIR) was calculated from date of 1 st complete remission to 1 st relapse or death in complete remission.
Relapse-free survival (RFS) was determined from dates of 1 st complete remission to 1 st relapse. Subjects achieving complete remission (N=208) were included in analyses of predictive variables for CIR and RFS. Differences across groups were compared using Pearson Chi-square analysis or Fisher exact test for categorical data and the Mann-Whitney U test or Student t-test for continuous variables. Receiver operating characteristic (ROC) curves were constructed to evaluate sensitivity and specificity of DPEP1 transcript levels to estimate CIR. Youden Index was used to calculate the optimal cutoff for high and low transcript levels 21 We then compared DPEP1 transcript levels in subjects with B-cell ALL in complete remission and relapse. Transcript levels decreased to a level like normals in subjects in complete remission but were increased at relapse ( Figure 1S -A). Sequential determinations of DPEP1 transcript levels in 9 subjects are displayed in Figure 1S -B.
Results
DPEP1 is highly-expressed in bone marrow lymphoblasts from subjects
DPEP1 transcript level is independently associated with CIR and RFS in subjects with common B-cell ALL
To interrogate the predictive impact of DPEP1 transcript levels on outcomes， we analyzed CIR and RFS in subjects with common B-cell ALL achieving complete remission. Characteristics were summarized in 
DPEP1 promotes the proliferation and survival of leukemia cell lines
To determine the functional significance of DPEP1 expression in vitro we used a lentivirus vector to knock down DPEP1 in the BV173 cell line and DPEP1 over-expressing (OE) cell lines were derived from BV173 and BALL-1 cells.
The over-expression and knockdown efficiency were verified by RT-PCR ( Figure 1A ) and western blot analyses ( Figure 1B) .
We first determined whether DPEP1 could alter proliferation and cell-cycle of leukaemia cells. BV173 cells over expressing DPEP1 displayed increased proliferation ( Figure 1C ) and more rapid cell-cycle progression (Figure 1D , E) compared with controls. Knockdown of DPEP1 resulted in a significant decrease in proliferation ( Figure 1F ) and slowed cell-cycle progression in BV173 cell lines ( Figure 1G, H) . The effect of DPEP1 was further confirmed in DPEP1-OE BALL-1 cell lines ( Figure 1I , J and K). Next, we detected whether DPEP1 could influence cell death in vitro. Apoptosis was relatively rare in control cell lines and DPEP1-OE did not markedly affect this rate ( Figure 1L ).
However, DPEP1-KD significantly increased apoptosis in the BV173 cell line( Figure 1L ). To confirm the role of DPEP1 in the survival and proliferation of B-cell ALL cells we performed clonality assays. Colony numbers were markedly increased in DPEP1-OE cells but decreased in DPEP1-knockdown cells compared with vector controls (Figure 1M, N) . In addition, migration ( Figure 1O) and invasion ( Figure 1P ) were significantly enhanced in DPEP1-OE BV173 cells but attenuated in DPEP1-knockdown cells detected by transwell assays.
These data suggest DPEP1 transcription favors proliferation and survival of B-cell ALL cell lines.
DPEP1 improves the survival of leukaemia cells exposed to anti-leukaemia drugs
We next studied interactions between DPEP1 expression and cell viability in cultures with anti-leukaemia drugs including dexamethasone, daunorubicin, cytarabine and imatinib (BV173 is a BCRABL1-positive). DPEP1-OE B-ALL-1 cells were more viable after cultures with dexamethasone, daunorubicin or imatinib compared with controls (Figure 2A-D) . DPEP1-OE BV173 cells showed the same trend of increased viability in the presence of anti-leukaemia drugs ( Figure 2E-H) , whereas DPEP1-KD BV173 cells had a significant decrease in viability under these conditions ( Figure 2I -L).
DPEP1 promotes the growth and survival of leukemia cells in vivo
Xeno-transplants were done with DPEP1-OE and DPEP1-KD cells to further investigate in vivo effects of DPEP1 expression. Knockdown of DPEP1 markedly decreased tumor growth compared with controls ( Figures 3A and B) .
In contrast, tumors were larger in DPEP1-OE cells ( Figure 3A and B) compared with controls. Histological examination showed more abundant blood sinuses in DPEP1-OE cell-derived tumors but a larger necrotic area in tumors derived from DPEP1-KD cells ( Figure 3C ). TUNEL staining confirmed increased apoptosis in specimens from the DPEP1-KD group compared with those from the vector controls corroborating the in vitro findings on apoptosis ( Figure 3D ).
Pathways involved in DPEP1-mediated alterations
To gain mechanistic insight into potential effector molecules involved in the increased proliferation and survival resulting from DPEP1 expression, we examined changes in several leukemia cell growth-and apoptosis-related proteins in BV173 cells. Levels of p-mTOR and CDK4 were largely unaffected by DPEP1 expression ( Figure 4A ). Phosphorylation of ERK was down-regulated in DPEP1-OE and DPEP1-KD cells and strongly inhibited in KD cells ( Figure 4A ). Phosphorylation of p38 was not markedly-affected in Figure 4A ). Level of pro-apoptotic p53 was increased after DPEP1 inhibition although there were no changes in DPEP1-OE cells consistent with the apoptosis assessments in vitro and in vivo ( Figure 4A ).
Next, we studied p-CREB and p53 expression in mouse tumors. Immune histochemistry studies detected high levels of pCREB in DPEP1-OE tumors compared with controls ( Figure 4B ). However, p53 was highly expressed in DPEP1-KD tumors compared with tumors from the other groups ( Figure 4C ).
These data suggest DPEP1 silencing favors an apoptotic, growth-inhibition phenotype whereas DPEP1-OE cells favors a proliferative phenotype.
Activation of pCREB pathway is responsible for DPEP1-mediated proliferation and anti-apoptosis in B-cell-ALL cell lines
To confirm the role of pCREB in DPEP1-mediated effects， we inhibited pCREB in BV173 DPEP1-OE cells with KG-501 ( Figure 5A ). pCREB-inhibition (12.5µM) reversed the increased proliferation of DPEP1-OE cells( Figure 5B ). This effect was confirmed in cell-cycle analyses where a decrease in the proportion of KG-501-treated DPEP1-OE cells in S-phase ( Figure 5C ).
Conversely, blocking pCREB induced an apoptotic phenotype of BV173 cell lines ( Figure 5D ). These data suggest phosphorylation of CREB by increased expression of DPEP1 is responsible for the changes in the growth and apoptosis of DPEP1-modified BV173 cell lines.
p53 is involved in DPEP1 silencing-induced apoptosis and growth inhibition
To verify the effect of p53 in DPEP1-KD cells we used PFT-a, a p53 inhibitor.
Inhibition of p53 significantly reversed the proliferation defect in DPEP1-KD cells ( Figure 5E ). Treatment with PFT-a slightly reversed decreased proliferation in DPEP1-KD cells ( Figure 5F) . Similarly, suppression of p53 promoted progression of quiescent cells (G 0 /G 1 phase) into S and G 2 phase ( Figure 5G) . The pro-apoptotic phenotype observed in DPEP1-KD cells was markedly decreased by PFT-a treatment ( Figure 5H ). Taken together, these data indicated a critical role for p53 in DPEP1 silencing-induced apoptosis and growth defects in BV173 cells.
Discussion
We found markedly-increased DPEP1 transcript levels at diagnosis in bone marrow lymphoblasts from adults with B-cell ALL compared with normals.
Transcript levels decreased in subjects achieving a complete remission but increased up on relapse. In multivariable analyses DPEP1 transcript levels at diagnosis, a positive MRD-test result in complete remission, not receiving a transplant and having BCRABL1 were significantly-associated with a higher CIR and worse RFS. Failure to detect significant correlations between predictive variables such as cytogenetics, WBC levels at diagnosis and IZKF1-deletion with CIR and/or survival is likely explained by 2 considerations:
(1) much of the impact of these variables operates on the likelihood of achieving a complete remission whereas we analyzed only subjects in complete remission; (2) subjects with high-risk features such as adverse cytogenetics received different therapies than subjects without these features such as an transplant and/or tyrosine kinase-inhibitor therapy.
Our analyses of variables associated with CIR and RFS was cofounded by high incidences of protocol violations regarding transplants. To address this, we therefore did the sensitivity analyses analyzing only subjects who received their protocol designated therapy. Only DPEP1 transcript levels remained significantly-associated with CIR and RFS in this cohort. However, we urge caution in accepting this conclusion without external validation.
To understand why DPEP1 expression might correlate with clinical outcomes we used gain-and loss-of-function cell lines to understand the possible mechanism underlying these associations. DPEP1 over-expression increased proliferation and survival of B-cell ALL cell lines in vitro and in a xeno-transplant model. DPEP1 knockdown had converse effects.
Dysregulation or aberrant activation of pro-survival and -proliferation signaling cascades in leukemia is usually linked to altered drug sensitivity and resistance 22 . Not surprisingly, we found DPEP1 over-expression increased resistance to anti-leukaemia drugs.
We also studied changes in several growth-and survival-related pathways in BV173 cells. PI3K-AKT has been identified as a central survival pathway downstream of the B-cell receptor central to normal or neoplastic B-cell development 23 . We detected similar trends in AKT phosphorylation and DPEP1 expression suggesting an involvement of p-AKT in pro-survival mechanisms mediated by DPEP1.
Transcription factors are key regulators of normal and leukaemia cell proliferation, survival and self-renewal 24 . CREB is over-expressed and constitutively phosphorylated in several human cancers including AML 25, 26 . We found pCREB levels were increased in parallel with DPEP1 expression and that down-regulation of DPEP1 correlated with up-regulation of p53 favouring cell apoptosis rather than proliferation and survival.
There are several important limitations to our study including small sample size, substantial protocol violations and lack of an external validation cohort. Also, subjects were not randomly-assigned to receive tyrosine kinase-inhibitor and/or allotransplant. Because of these limitations, conclusion regards the predictive impact of DPEP1 of CIR and RFS requires confirmation in a cohort of uniformly-treated subjects.
In summary, our data implicate DPEP1 expression in the biology of common B-cell ALL in adults. We report clinical correlates, namely an association between high transcript levels and an increased CIR and worse RFS and provide a potential biological basis for these correlations. If confirmed, analyzing DPEP1 transcript levels at diagnosis could help predict therapy-outcomes. Moreover, regulation of DPEP1 expression could be a therapy target in B-cell ALL. 
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